 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Neoadjuvant immunotherapy can improve the pathological remission rate of patients with stage III-IVA CSCC-HN

Clin Cancer Res: Neoadjuvant immunotherapy can improve the pathological remission rate of patients with stage III-IVA CSCC-HN

 Last Update: 2021-08-26
 Source: Internet
 Author: User

Tags

trial size

advanced

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The standard treatment for locally advanced, resectable squamous cell carcinoma of the head and neck (CSCC-HN) is radiotherapy after surgery; however, the treatment can be cosmetically and functionally devastating, and many patients will relapse

A phase 2 clinical trial recently published in the journal " Clin Cancer Res ", " Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck ", evaluated neoadjuvant immunotherapy in such patients In the efficacy and safety

Clin Cancer Res Clin Cancer Res Clin Cancer Res Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckImmunity

The trial recruited newly diagnosed or recurrent stage III-IVA CSCC-HN patients and received two courses of neoadjuvant PD-1 inhibitory therapy

Changes in tumor volume after treatment

A total of 20 patients were recruited, of which 7 had recurrent disease

6 (30%) patients achieved partial remission, 14 (70%) achieved pCR (n=11) or MPR (n=3), 6 (30%) patients achieved partial remission, and 14 (70%) ) Obtained pCR (n=11) or MPR (n=3)

After a median follow-up of 22.

The 12-month DSS, DFS, and OS rates are 95%, 89.

Whether to relieve the number of immune cells in the patient's tumor microenvironment before and after treatment

Gene expression analysis showed that patients with pCR or MPR had an inflammatory tumor microenvironment, while CyTOF analysis showed that patients with pCR had a significant enrichment of memory CD8+ T cells

In summary, neoadjuvant immunotherapy can be safely used for locally advanced, resectable CSCC-HN patients, and can induce a higher pathological remission rate

Neoadjuvant immunotherapy can be safely used in patients with locally advanced, resectable CSCC-HN, and can induce a higher pathological remission rate.

Original source:

Renata Ferrarotto, et al.

Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.